Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Certolizumab pegol demonstrates positive results in two Phase III Crohn’™s disease trials

28.07.2005


UCB today announced positive results for the two pivotal Phase III trials (PRECISE 1 and 2) of certolizumab pegol (CDP870) in the induction and maintenance of clinical response in moderate to severe active Crohn’TMs disease. The PRECiSE trials assessed the safety and efficacy of CIMZIATM compared to placebo over a 26 week period, in a total of 1330 patients with active Crohn’TMs disease.

Data from PRECiSE 1 and 2 will be presented in more detail at the major forthcoming gastroenterology medical congresses.

About Crohn’TMs Disease

Crohn’TMs disease is a chronic inflammatory disease of the gastrointestinal tract with the disease typically localized in the terminal part of the ileum (a portion of the small intestine) and right colon (a portion of the large intestine). Crohn’TMs disease affects almost 1 million patients worldwide, with the disease typically appearing early in life. Crohn’TMs disease is characterized by a variety of symptoms, although different in every individual, and may include persistent diarrhea, abdominal pain, and at times loss of appetite/weight, fever or rectal bleeding . Unfortunately there is no single test to diagnose Crohn’TMs disease and because it can often imitate other gastroenterological conditions, patients may experience a lengthy diagnosis process. Although Crohn’TMs disease affects males and females equally of all ages, the most affected in the U.S. are 20-29 year olds and 30-39 year olds . The disease also occurs in young children and adults over 70 years of age. In addition, American Jews of European backgrounds are more likely than the general population to develop Crohn’TMs disease.

Crohn’s Disease - United States (Prevalence)

Yrs of age 2005 %
0-9 30906 8%
10-19 32491 9
20-29 145598 39%
30-39 68205 18%
40-49 23525 6%
50-59 41850 11%
60-69 11669 3%
70-79 11656 3%
80+ 7131 2%


About CIMZIATM

CIMZIATM is a PEGylated Fab’TM fragment of a humanized anti-TNF alpha monoclonal antibody, with high affinity for both soluble and membrane-bound TNF alpha. CIMZIATM is also currently the subject of Phase III clinical trials in rheumatoid arthritis.

About UCB

UCB (www.ucb-group.com) is a global biopharmaceutical leader dedicated to the research, development and commercialization of innovative products in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders and oncology. UCB employs over 8,500 people operating in over 40 countries. UCB is listed on the Euronext Brussels with a market capitalization of approximately € 5.8 billion. Worldwide headquarters are located in Brussels, Belgium.

UCB Pharma, Inc. is the North American subsidiary of UCB, with U.S. headquarters located in Smyrna, Georgia. UCB’TMs key products in the U.S. are Keppra® (levetiracetam), Zyrtec®’ (cetirizine HCl), Tussionex® CIII (hydrocodone polistirex/chlorpheniramine polistirex), and Metadate® CD CII (methylphenidate HCl, USP).

’ Zyrtec is licensed to and co-promoted with Pfizer, Inc. in the United States.

Lisa Garman | EurekAlert!
Further information:
http://www.ucb-group.com

More articles from Medical Engineering:

nachricht Skin patch dissolves 'love handles' in mice
18.09.2017 | Columbia University Medical Center

nachricht Medicine of the future: New microchip technology could be used to track 'smart pills'
13.09.2017 | California Institute of Technology

All articles from Medical Engineering >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Comet or asteroid? Hubble discovers that a unique object is a binary

21.09.2017 | Physics and Astronomy

Cnidarians remotely control bacteria

21.09.2017 | Life Sciences

Monitoring the heart's mitochondria to predict cardiac arrest?

21.09.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>